Company Type Of Number Of Amount Investors; Placement Agents;
(Symbol) Financing Shares, Units Raised (M) Details (Date)
Or Warrants (M)
Alpha-Beta Tech- Private ND $3 The company agreed to sell $3M in convertible
nology Inc. (ABTI) placement preferred stock to a single institutional investor;
the investor bought $1.5M immediately and
will purchase the rest on the effectiveness of
a resale registration statement (10/22)
Creative Sale of OP-1 $20 Creative BioMolecules sold its OP-1 manufacturing
BioMolecules Inc. manufacturing rights and facilities to development partner
(CBMI) rights and Stryker Corp.; Creative gets increased royalties
facilities on sale of the product for orthopedic and dental
reconstruction in place of manufacturing profits
per terms of the partners' original agreement (10/16)
Cytogen Corp. Equity line $12 Cytogen secured a $12M common stock equity line
(CYTO) from Kingsbridge Capital, an institutional investor
based in Ireland; the company can draw up to $12M
in cash over 2 years in exchange for common stock
(at a 15% discount to market); Cytogen must register
the shares before it can draw down the cash (10/26)
Medarex Inc. Payment of $15.5 Medarex received a $15M principal payment and
(MEDX) principal and $0.5M in interest from Cell Genesys Inc. The
interest on note payment is in satisfaction of a note issued in con-
nection with a cross-license and settlement agree-
ment from 3/97 between Medarex subsidiary
GenPharm International Inc. and Cell Genesys (10/1)
RiboGene Inc. Equipment $2 Finova Capital Corp. will provide RiboGene
(RBO) financing with $2M in financing in the form of secured
equipment loans over the next 12 months (10/7)
TOTAL: $52.5M
ND = Not disclosed, reported and/or available; S = Shares; U = Units; W = Warrants
The financings in this chart include loans, bridge financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements.